You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Search all journals

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

Copyright © 2026 by Sage Publications.京ICP备09090397号-11

Search results

Search results page

Articles (107)

Journals (0)

1-10 of 107 results for HR-positive and HER2-negative

Sort by:

Relevance

Select all

Select all

Sort by:

Relevance

Select article: Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study

Open access

Research article

First published 2024

Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR-positive and HER2-negative advanced breast cancer: results from a phase Ib study

Qingyuan Zhang, Pin Zhang, Min Yan [...]

Therapeutic Advances in Medical Oncology

Select article: Predictive Value of Magee Equation 3 for Tumor and Axillary Response to Neoadjuvant Chemotherapy in HR-Positive,HER2-Negative Breast Cancer

Retricted access

Research article

First published 2026

Predictive Value of Magee Equation 3 for Tumor and Axillary Response to Neoadjuvant Chemotherapy in HR-Positive,HER2-Negative Breast Cancer

Mustafa Onur Beştaş, Erkan Güler, Ahmet Dağ [...]

The American Surgeon™

Select article: Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated,HR-positive,HER2-negative invasive breast cancer: A systematic review

Retricted access

Research article

First published 2025

Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated,HR-positive,HER2-negative invasive breast cancer: A systematic review

Chris Larck, Joseph B Elmes, R. Wesley Haynes [...]

Journal of Oncology Pharmacy Practice

Select article: HR-positive/HER2-negative breast cancer arising in patients with or without BRCA2 mutation: different biological phenotype and similar prognosis

Open access

Research article

First published 2024

HR-positive/HER2-negative breast cancer arising in patients with or without BRCA2 mutation: different biological phenotype and similar prognosis

Pu-Chun Li, Yi-Fan Zhu, Jia-Ni Pan [...]

Therapeutic Advances in Medical Oncology

Select article: Efficacy and Safety of Ribociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR-Positive/HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Open access

Research article

First published 2025

Efficacy and Safety of Ribociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR-Positive/HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Reechashree Dhungana, Parikshit Prasai, Bishal Paudel [...]

Clinical Medicine Insights: Oncology

Select article: Managing advanced HR-positive,HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Open access

Editorial

First published 2018

Managing advanced HR-positive,HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Lorenzo Rossi, Amelia McCartney, Emanuela Risi [...]

Therapeutic Advances in Medical Oncology

Select article: A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease)

Open access

Research article

First published 2025

A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease)

Bora Lim, Angela Marx, Megumi Kai [...]

Therapeutic Advances in Medical Oncology

Select article: Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety

Open access

Case report

First published 2024

Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety

Ünal Metin Tokat, Şevval Nur Bilgiç, Esranur Aydın [...]

Therapeutic Advances in Medical Oncology

Select article: The association between HER2-low expression and prognosis of breast cancer: a systematic review and meta-analysis

Open access

Research article

First published 2023

The association between HER2-low expression and prognosis of breast cancer: a systematic review and meta-analysis

Yuyao Tang, Guoshuang Shen, Yuanfang Xin [...]

Therapeutic Advances in Medical Oncology

Select article: Comparison of clinicopathological characteristics and response to neoadjuvant systemic therapy in patients with HER2-low-positive and HER2-zero breast cancer

Retricted access

Research article

First published 2023-4

Comparison of clinicopathological characteristics and response to neoadjuvant systemic therapy in patients with HER2-low-positive and HER2-zero breast cancer

Wenjie Shi, Xinyu Wan, Jinzhi He [...]

Journal of Investigative Medicine

1
2
3
•••
11
10 / page

Article type

Publication date

Subjects

Access